BPA Call 36E79720A0019-36C24921N0323
Award Date
1/26/21
Potential Completion Date
1/29/21
Potential Value
$284K
Federal Agency
Veterans Integrated Service Network 9
Ultimate Awardee
Not listed
NAICS Category
325412 - Pharmaceutical Preparation Manufacturing
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
East Hanover, NJ 07936, USA
Solicitation Procedures
Multiple Award, Fair Opportunity
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award to Novartis Pharmaceuticals Corporation, doing business as NPS, is for the delivery of Kymriah, a specialized cell therapy cancer treatment, to the U.S. Department of Veterans Affairs (VA) Veterans Health Administration (VHA). The contract is issued as a delivery order against Novartis' existing Federal Supply Schedule (FSS) 61-IB contract for pharmaceuticals and drugs, which has a potential value of $5.4 billion and runs through August 2025. The specific delivery...
The Department of Veterans Affairs Veterans Health Administration awarded a $283,567.92 delivery order to Novartis Pharmaceuticals Corporation (doing business as NPS), a foreign-owned for-profit manufacturer of pharmaceuticals and drugs. The order was placed against Novartis' Federal Supply Schedule 61-IB contract for pharmaceuticals and drugs, which has a total potential value of $5.4 billion and runs through August 2025. The delivery order was for Novartis' Kymriah, a chimeric antigen receptor...
This is a delivery order awarded by the Department of Veterans Affairs (VA) Veterans Health Administration to Novartis Pharmaceuticals Corporation, a foreign-owned, for-profit manufacturer, to provide the chimeric antigen receptor T-cell therapy drug Kymriah. The order, valued at $283,567.92, was placed against Novartis' Federal Supply Schedule (FSS) contract for Pharmaceuticals and Drugs (FSS-61-IB) and has a firm fixed price. The order supports the VA's medical programs and does not have a...
The Department of Veterans Affairs Veterans Health Administration awarded a delivery order to Novartis Pharmaceuticals Corp., doing business as NPS, for the specialized cancer medication KYMRIAH (TISAGENLECLEUCEL). The $283,526.57 firm fixed price order was placed against Novartis' Federal Supply Schedule 61-IB contract for pharmaceuticals and drugs, which has a total potential value of $5.4 billion and extends through August 2025. Novartis, a foreign-owned for-profit manufacturer, has...
This firm fixed-price delivery order was awarded by the Department of Veterans Affairs Veterans Health Administration to Novartis Pharmaceuticals Corporation, a foreign-owned, for-profit manufacturer, to provide the Kymriah chimeric antigen receptor T-cell therapy to the Nashville VA Medical Center. The order, valued at $283,526.57, was issued against Novartis' Federal Supply Schedule 61-IB contract for pharmaceuticals and drugs, which has a total potential value of $5.4 billion. Kymriah is a...
The Department of Veterans Affairs (VA) awarded a $283,526.57 firm fixed price delivery order to Novartis Pharmaceuticals Corporation, a foreign-owned for-profit manufacturer, to provide the emergency cancer treatment Tisagenlecleucel under the VA's Federal Supply Schedule contract for pharmaceuticals and drugs. The delivery order was issued by the VA Veterans Health Administration's Veterans Integrated Service Network 9 and did not have a set-aside designation. Novartis holds a $5.4 billion...
This is a firm fixed-price delivery order awarded by the Department of Veterans Affairs (VA) to Novartis Pharmaceuticals Corporation (Novartis), a foreign-owned, for-profit manufacturer of pharmaceutical products. The $283,526.57 order is for Novartis' cell therapy treatment Tisagenlecleucel, which is used to treat certain types of cancer. The order was placed through Novartis' existing Federal Supply Schedule (FSS) contract for pharmaceuticals and drugs (FSS-61-IB), which allows the VA to...
This federal contract award is for the delivery of the radiopharmaceutical PLUVICTO to the Cleveland VA Medical Center (VAMC). The $598,124.52 firm fixed price delivery order was issued against Novartis Pharmaceuticals Corporation's Federal Supply Schedule (FSS) contract for pharmaceuticals and drugs (FSS-61-IB). Novartis, a foreign-owned for-profit manufacturer, has provided specialized cancer therapies like Kymriah to VA networks and facilities under previous orders and agreements. This...
This federal contract award, valued at $4,106,391.52, was issued by the Veterans Integrated Service Network 17 (VISN 17) of the U.S. Department of Veterans Affairs (VA) to Novartis Pharmaceuticals Corporation, a foreign-owned for-profit manufacturer of pharmaceutical products. The contract is for the delivery of the cancer therapies LUTATHERA and PLUVICTO, which are being provided to support VA medical programs. The contract was awarded under Novartis' existing Federal Supply Schedule (FSS)...
The Department of Veterans Affairs (VA) awarded a $283,526.57 delivery order to Novartis Pharmaceuticals Corporation, doing business as NPS, for emergency drug orders to support the Tennessee Valley Healthcare System (TVHS). This order was placed against Novartis' Federal Supply Schedule (FSS) 61-IB contract for pharmaceuticals and drugs, which has a total potential value of $5.4 billion and runs through August 2025. Novartis, a foreign-owned, for-profit manufacturer, has provided specialized...